POST: A Prospective Observational Study of TPIAT
Study Details
Study Description
Brief Summary
Multi-center, prospective, observational cohort study of patients undergoing total pancreatectomy with islet autotransplantation (TPIAT)
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Patients who are undergoing TPIAT at one of the participating center are invited to participate in this observational study, with 450 participants anticipated. The aims of the study are:
Aim 1: To determine (1a) whether patient and disease characteristics are associated with favorable pain and health-related quality-of-life outcomes (HRQOL) after TPIAT; (1b) the optimal timing of the TPIAT intervention to resolve pain and improve HRQOL; and (1c) in a subset of patients, the impact of central sensitization on pain resolution.
Aim 2: To determine (2a) whether patient and disease characteristics are associated with favorable glycemic outcomes from the IAT procedure; and (2b) the optimal timing of TPIAT to obtain post-surgical insulin independence.
Aim 3: To determine the cost-effectiveness of TPIAT.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
TPIAT patients undergoing total pancreatectomy with islet autotransplant. |
Procedure: TPIAT
The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
|
Outcome Measures
Primary Outcome Measures
- Pain Reduction [Mos 6, Years 1, 2, 3, 4 after surgery]
Visual Analog Pain Scale
- Quality of Life [Mos 6, Years 1, 2, 3, 4 after surgery]
Physical Component Summary Score from SF-12
- Quality of Life [Mos 6, Years 1, 2, 3, 4 after surgery]
Mental Component Summary Score from SF-12
- Diabetes [Mos 6, Years 1, 2, 3, 4 after surgery]
Proportion of patients insulin independent
Secondary Outcome Measures
- Opioid Use [Mos 6, Years 1, 2, 3, 4 after surgery]
proportion off opioid analgesics
- Opioid Use [Mos 6, Years 1, 2, 3, 4 after surgery]
Morphine Equivalents (avg daily ME)
- Glycemic Control [Mos 6, Years 1, 2, 3, 4 after surgery]
HbA1c level
- Insulin Dose [Mos 6, Years 1, 2, 3, 4 after surgery]
Insulin Dose (U/day)
- Islet Graft Function [Mos 6, Years 1, 2, 3, 4 after surgery]
Proportion with Islet Graft Function (C-peptide + or Off Insulin)
- Severe Hypoglycemia Episodes [Mos 6, Years 1, 2, 3, 4 after surgery]
Proportion of patients with Severe Hypoglycemia
- Pain Interference [Mos 6, Years 1, 2, 3, 4 after surgery]
Pain interference Score (PROMIS scale)
Eligibility Criteria
Criteria
Inclusion Criteria:
- Any patient with chronic or recurrent acute pancreatitis undergoing total or completion pancreatectomy with islet autotransplantation at a participating center.
Exclusion Criteria:
-
Partial pancreatectomy
-
TPIAT performed for a diagnosis other than chronic or recurrent acute pancreatitis (for example benign or malignant pancreatic tumor)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California, San Francisco | San Francisco | California | United States | 94143 |
2 | The University of Chicago Medical Center | Chicago | Illinois | United States | 60637 |
3 | University of Louisville | Louisville | Kentucky | United States | 40292 |
4 | Johns Hopkins Hospital | Baltimore | Maryland | United States | 21287 |
5 | University of Minnesota | Minneapolis | Minnesota | United States | 55455 |
6 | Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | United States | 03756 |
7 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
8 | Cleveland Clinic | Cleveland | Ohio | United States | 44195 |
9 | The Ohio State University Wexner Medical Center | Columbus | Ohio | United States | 43210 |
10 | University of Pittsburgh Medical Center, Thomas E. Starzl Transplantation Institute | Pittsburgh | Pennsylvania | United States | 15213 |
11 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
12 | Baylor University Medical Center | Dallas | Texas | United States | 75246 |
Sponsors and Collaborators
- University of Minnesota
- Baylor Health Care System
- Medical University of South Carolina
- University of Chicago
- University of Pittsburgh Medical Center
- Dartmouth-Hitchcock Medical Center
- Johns Hopkins University
- Children's Hospital Medical Center, Cincinnati
- Ohio State University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PEDS-2019-26517
- R01DK109124